Furthermore, both drugs reduce tau hyperphosphorylation [92, 101] and improve synaptic plasticity, increasing synaptic proteins synaptophysin, vesicle-associate membrane proteins and PSD95 [95], while restoring BDNF levels [102] in both transgenic and Aß-injected AD models. Here, MAPT is linked to Alzheimer disease.